NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25. The study will provide safety and ...

Following a year of strategic expansion, European medicine-related companies are advancing their operations in Vietnam.

The UK MHRA has validated Bavarian Nordics’ marketing authorisation application for its single-dose chikungunya vaccine.

Getting patients access to treatments they need – without which they will die – is the ‘biggest burden of my life’, says Prof ...

The European orphan drug market is growing and is already comparable in size and scope to the US market. The European Union ...

Epinephrine is the only proven anaphylaxis treatment to reduce the risk of hospitalization and death. However, only 21% of ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

Ocugen (OCGN) announced that the European Commission, EC, has provided a positive opinion from the European Medicines Agency’s, EMA, Committee ...

The European Medicines Agency and Belgium’s Federal Agency for Medicines and Health Products have approved a Phase 2 challenge study on EV25, an antiviral therapeutic from Eradivir. The approval ...

From a historic vaccine approval to a $50bn investment reshaping US drug manufacturing, February brought major pharma news to ...